At a glance
ClinicalIndex Comparison RecordN/ACompleted· 408 enrolled
Drug / intervention
SLCO1B1 Genotypegenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Safety and Efficacy of Pharmacogenetics in Veteran Care
In Brief
A clinical study evaluating SLCO1B1 Genotype for Cardiovascular Disease. Completed, enrolled 408 participants across 1 site.
Detailed Summary
This study will determine whether using a genetic test (for the SLCO1B1 gene) can help patients and providers choose the right type and dose of cholesterol-lowering statin medications to lower the risk of cardiovascular disease, while minimizing the muscle pain side effects that sometimes occur with statins.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCardiovascular Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedAug 2016
Primary CompletionDec 2020
TodayJul 2026
First PostedAug 18, 2016
Enrollment StartAug 1, 2016
Primary CompletionDec 31, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.9 years ago
Interventions
SLCO1B1 Genotypegenetic
Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.